Form D · Biotechnology
MaveriX Oncology, Inc.
Palo Alto, CA · CIK 0001675815
Offering snapshot reported Oct 9, 2019 · SEC filing
- Reported sold
- $1.8M Offering amount: $20M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 24, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2019 | Initial | $1,800,000 | No comparison | 1 | SEC filing |
| Jun 3, 2016 | Initial | $999,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $180K
- Form D file number
- 021-350656
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Katalyst Securities LLC | None | Katalyst Securities LLC · CRD 112494 |
Source: Form D, filed Oct 9, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven A. Everett | Director, Executive |
| Kim Nearing | Director |
| Rick Panicucci | Director |
| Riccardo Panicucci | Director |
| Norbert Prenzel | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
435 Middlefield Road
Palo Alto, CA, 94301
Palo Alto, CA, 94301